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Background: We report here the prognostic value of ploidy and digital tumour-stromal morphometric analyses using material
from 2624 patients with early stage colorectal cancer (CRC).
Patients and methods: DNA content (ploidy) and stroma-tumour fraction were estimated using automated digital imaging
systems and DNA was extracted from sections of formalin-fixed paraffin-embedded (FFPE) tissue for analysis of microsatellite
instability. Samples were available from 1092 patients recruited to the QUASAR 2 trial and two large observational series
(Gloucester, n¼ 954; Oslo University Hospital, n¼ 578). Resultant biomarkers were analysed for prognostic impact using 5-year
cancer-specific survival (CSS) as the clinical end point.
Results: Ploidy and stroma-tumour fraction were significantly prognostic in a multivariate model adjusted for age, adjuvant
treatment, and pathological T-stage in stage II patients, and the combination of ploidy and stroma-tumour fraction was found
to stratify these patients into three clinically useful groups; 5-year CSS 90% versus 83% versus 73% [hazard ratio (HR)¼ 1.77 (95%
confidence interval (95% CI): 1.13–2.77) and HR¼ 2.95 (95% CI: 1.73–5.03), P< 0.001].
Conclusion: A novel biomarker, combining estimates of ploidy and stroma-tumour fraction, sampled from FFPE tissue,
identifies stage II CRC patients with low, intermediate or high risk of CRC disease specific death, and can reliably stratify clinically
relevant patient sub-populations with differential risks of tumour recurrence and may support choice of adjuvant therapy for
these individuals.
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Introduction
Biomarkers are being used increasingly to select populations of
cancer patients who are likely to benefit most from treatment and
avoid life threatening toxicity [1, 2]. However, the dominant
management decision in the adjuvant setting is whether any
treatment should be offered at all, given its relatively marginal
benefits [3]. For example, a 6-month postoperative course of 5-
fluorouracil and folinic acid or capecitabine improves overall sur-
vival (OS) by around 3%–5% for patients with stage II or IIIA
colorectal cancer. The vast majority (75%–80%) of these patients
will be cured by surgery alone; 15%–20% will recur despite adju-
vant chemotherapy; there is likely to be a chemotherapy associ-
ated death rate of 0.5%–1%; and 20% of patients will suffer
significant side effects [4–7]. The risk–benefit ratio is therefore
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marginal, but would be positively skewed if it were possible to
define a subgroup at higher risk of recurrence and cancer specific
death.
Although clinically validated prognostic biomarkers would
facilitate adjuvant therapeutic decisions, until recently, none
have been sufficiently robust for routine clinical application. We
recently reaffirmed the prognostic value of DNAmismatch repair
(MMR) status in 1913 patients enrolled in the QUASAR trial [8]
and identified those 12%–15% of MMR-deficient, stage II
patients at a reduced risk of recurrence and in whom adjuvant
therapy is not indicated [9, 10]. Similarly, a clinical argument has
been presented for use of an RNA signature-based risk score to
stratify T3 N0, MMR-proficient colorectal tumours [11]. A num-
ber of studies have shown that manually assessed stroma fraction
is a prognostic marker in colorectal cancer (CRC) [12–15].
Further subdivision was investigated by Angell and Galon [16],
who explored the prognostic impact of immune infiltrates.
The aim of the present study was to undertake morphometric
and molecular analysis of a series of primary CRC specimens col-
lected retrospectively from patients entered into a trial
(QUASAR) of adjuvant therapy and two large observational
cohorts to validate the combination of ploidy and stromal frac-
tion as a potentially clinically useful prognostic marker.
Methods
QUASAR 2 study
A total of 1952 patients, who had undergone surgery for stage III/high
risk stage II CRC, were randomly assigned to receive capecitabine alone,
comprising a 3-week cycle of 1250mg/m2 twice daily for 14 days followed
by a 7 days break for a total of eight cycles, or the same in combination
with bevacizumab, 7.5mg/kg intravenous infusion over 90minutes on
day 1 of each 3-week cycle. The primary end point was 3-year disease-free
survival (DFS) with OS a secondary end point.
The study was undertaken in accordance with the protocol, good clini-
cal practice, the EU Directive 2001/20/EC and 2005/28/EC, and the
Declaration of Helsinki, and was approved by West Midlands Research
Ethics Committee, United Kingdom (REC reference: 04/MRE/11/18). An
independent data safety monitoring committee carried out annual safety
reviews. This trial is registered, number ISRCTN 4513315.
Gloucester cohort
The Gloucester Colorectal Cancer Study was carried out between 1988
and 1996 and recruited 1050 patients. A small proportion of the patients
(7% among stage II and 15% among stage III) received adjuvant therapy.
The prognostic impact of peritoneal involvement has been evaluated in
the colonic and rectal cancers in this cohort previously [17, 18]. The
Gloucestershire Local Research Ethics Committee, under reference 01/
21G, approved the study.
Oslo University Hospital—Aker cohort
This cohort is a consecutive series of 578 stages I–III colorectal cancer
patients treated at Oslo University Hospital—Aker, Norway, in the period
1993–2003. A minority of the patients received adjuvant therapy (1%
among stage II and 30% among stage III patients). The prognostic impact
of DNAploidy andmicrosatellite instability (MSI) status has been reported
in the same patient cohort previously [19, 20]. The study was carried out
according to the Helsinki Declaration and approved by the Norwegian
Regional Committees forMedical Research (REK; #1.2005.1629).
Tumour sampling
For analyses, the pathologist selected one tumour block deemed repre-
sentative from each patient, and annotated the whole epithelial tumour
region. Hence, no systematic selection was carried out.
DNA ploidy analysis
DNA ploidy analysis by image cytometry was carried out as previously
reported [21].
Tumour-stroma fraction
The tumour-stroma fraction was measured on the histological images
using developed proprietary software tools and analysis methods as
described in supplementary methods, available at Annals of Oncology
online. The method for automatically segmenting tumour-stroma in
HE-stained tissue sections (Supplementary Figure S1, available at Annals
of Oncology) was developed in a separate dataset where a pathologist eval-
uated the segmentation results during development. The cutoff value for
low and high stroma was taken from a previous study where stroma frac-
tion was manually assessed [12].
Statistical analysis
All pathological and laboratory assessments were undertaken blind to the
patients’ treatment allocation and clinical outcomes.
Five-year cancer-specific survival (CSS) was the end point common to
all datasets and was used for the individual and pooled analyses. For
QUASAR 2, survival time was calculated from date of randomisation. An
event was defined as cancer death within 5 years. Observations were cen-
sored at death from other causes or at 5 years after randomisation, which-
ever occurred first. For the Gloucester and Aker datasets, survival time
was calculated from surgery date.
For assessment of the prognostic value of variables, cancer-specificmor-
tality rates over the follow-up period of 5 years were analysed. Only varia-
bles that were significant in univariate analyses in the pooled dataset were
included in the multivariate analysis, with the exception of age. Estimated
survival functions were compared using the Mantel-Cox log-rank test in
univariate analysis of categorical variables and theWald chi-squared test in
multivariate analysis. Analyses were carried out using R version 3.1.3.
Results
Patient demography
The majority of patients had colon cancer (75%), median age of
68 years, a male preponderance (55% versus 45%), a majority of
stage III patients (53% versus 39% stage II and 7% stage I), with
stage II subjects having a higher proportion of MSI (18% versus
11%, Table 1). Stages II and III had more high stroma tumours
compared with stage I (13% versus 7%, supplementary Tables
S1A–C, available at Annals of Oncology online). All patients in the
QUASAR 2 cohort received chemotherapy (capecitabi-
ne6 bevacizumab), whereas 1% of the Aker and 7% of the
Gloucester stage II patients were treated with chemotherapy.
Univariate prognostic factors for CSS
Univariate analyses of the individual datasets are summarised in
supplementary Tables S1A–C, available at Annals of Oncology
online.
In the pooled dataset, the combination of ploidy and stroma
was statistically significant in stage II tumours (P< 0.001,
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Table 1. Distribution of relevant parameters
Variables QUASAR 2 Gloucester OUH-Aker Pa All hospitals
Age, years <0.001b
Mean6 SD 64610 70611 70612 68611
Range 27-88 28-94 30-94 27-94
Gender 0.004
Male 634 (58) 510 (53) 288 (50) 1432 (55)
Female 458 (42) 444 (47) 290 (50) 1192 (45)
Tumor site <0.001
Colon 882 (85) 641 (67) 406 (70) 1929 (75)
Rectum 158 (15) 313 (33) 172 (30) 643 (25)
Disease stage <0.001
Stage I 0 83 (9) 112 (19) 195 (7)
Stage II 394 (36) 358 (38) 277 (48) 1029 (39)
Stage III 698 (64) 513 (54) 189 (33) 1400 (53)
pT stage <0.001
pT1 17 (2) 14 (1) 27 (5) 58 (2)
pT2 70 (7) 70 (7) 103 (18) 243 (9)
pT3 569 (54) 422 (44) 414 (72) 1405 (55)
pT4 389 (37) 447 (47) 34 (6) 870 (34)
pN stage <0.001
pN0 381 (36) 442 (46) 388 (67) 1211 (47)
pN1 489 (47) 273 (29) 152 (26) 914 (35)
pN2 181 (17) 239 (25) 37 (6) 457 (18)
Histological grade <0.001
Well differentiated 42 (4) 141 (15) 58 (10) 241 (9)
Moderately differentiated 829 (80) 516 (54) 452 (79) 1797 (70)
Poorly differentiated 160 (16) 297 (31) 63 (11) 520 (20)
Stroma <0.001
Low 986 (90) 882 (92) 415 (72) 2283 (87)
High 106 (10) 72 (8) 163 (28) 341 (13)
Ploidy status 0.75
Diploid 326 (30) 296 (31) 182 (31) 804 (31)
Non-diploid 766 (70) 658 (69) 396 (69) 1820 (69)
Ploidy and stroma <0.001
Diploid and low stroma 309 (28) 286 (30) 159 (28) 754 (29)
Diploid and high stroma 17 (2) 10 (1) 23 (4) 50 (2)
Non-diploid and low stroma 677 (62) 596 (62) 256 (44) 1529 (58)
Non-diploid and high stroma 89 (8) 62 (6) 140 (24) 291 (11)
Ploidy and stroma 3 groups <0.001
Diploid and low stroma 309 (28) 286 (30) 159 (28) 754 (29)
Diploid and high stroma/non-diploid and low stroma 694 (64) 606 (64) 279 (48) 1579 (60)
Non-diploid and high stroma 89 (8) 62 (6) 140 (24) 291 (11)
Microsatellite instability status 0.037
Microsatellite stable 896 (88) NA 452 (84) 1348 (86)
Microsatellite instable 126 (12) NA 87 (16) 213 (14)
Adjuvant treatment <0.001
No 0 567 (89) 434 (90) 1001 (45)
Yes 1092 (100) 72 (11) 49 (10) 1213 (55)
Total number 1092 954 578 2624
aP-value for the comparison of variable between datasets.
bOne-way analysis of variance.
SD, standard deviation; NA, not available; OUH-Aker, Oslo University Hospital—Aker.
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supplementary Table S1D, available at Annals of Oncology
online). Diploid and low stroma tumours represented a patient
group with low cancer-specific mortality [5-year CSS 90% (95%
confidence interval (95% CI): 87% to 94%)], while diploid and
high stroma tumours together with non-diploid and low stroma
tumours constituted an intermediate group with increased
cancer-specific mortality compared with the low-risk group [5-
year CSS 83% (95% CI: 79% to 86%), hazard ratio (HR) 1.79
(95% CI: 1.17–2.73)]. Non-diploid and high stroma tumours
characterised a group of patients with high risk for cancer-
specific mortality [5-year CSS 73% (95% CI: 65% to 82%), HR
2.87 (95% CI: 1.71–4.82), Figure 1A]. Five-year OS for the low,
intermediate and high risk groups among stage II patients were
79%, 72% and 63%, respectively. Similarly, in QUASAR 2, 3-year
DFS rates were 92%, 85% and 72%, while the corresponding fig-
ures in the Aker dataset were 82%, 72% and 59%, respectively. In
the Gloucester dataset, DFS was not available.
The combined ploidy-stroma marker had a less marked prog-
nostic impact among stage III tumours (P¼ 0.050), with 5-year
CSS of 70% (95% CI: 64% to 76%) in the low-risk group, 68%
(95% CI: 64% to 71%) with HR 1.13 (95% CI: 0.88–1.45) in the
intermediate risk group, and 58% (95% CI: 50% to 67%) with
HR 1.50 (95% CI: 1.08–2.09) in the high-risk group (Figure 1B).
Five-year OS for the low, intermediate and high risk groups
among stage III patients were 61%, 59% and 48%, respectively.
Similarly, 3-year DFS rates in QUASAR 2 were 73%, 73% and
53%, while the corresponding figures in the Aker dataset were
67%, 46% and 50%, respectively.
Patients with pT4 tumours had an inferior prognosis com-
pared with pT3 tumours in both stage II and stage III [HR 1.42
(95% CI: 1.01–2.01), P¼ 0.043 and HR 2.81 (95%CI: 2.28–3.46),
P< 0.001, respectively].
Among stage III tumours, tumour differentiation was a signifi-
cant prognostic marker [HR 1.65 (95%CI: 0.88–3.11) for moder-
ate versus well differentiated and HR 4.49 (95% CI: 2.37–8.53)
for poor versus well differentiated tumours, P< 0.001].
The combination of pathological T-stage and degree of tumour
differentiation was not prognostic in stage II disease (Figure 2A),
whereas, among stage III patients, poorly differentiated pT4
tumours [224 of 1355 (17%)] have the worst outcome, while
poorly differentiated pT3 andmoderately differentiated pT4 [417
of 1355 (31%)] constitute an intermediate risk group (Figure 2A
and B).
MSI did not have a significant impact in univariate analyses
[MSI versus MSS HR¼ 0.73 (95% CI: 0.40–1.35), P¼ 0.32) in
stage II, and HR¼ 1.19 (95% CI: 0.75–1.87, P¼ 0.46) in stage III
disease].
QUASAR 2 patients receiving bevacizumab did not have a sig-
nificantly different prognosis than those that received capecita-
bine alone when stratifying for stroma content and stage,
indicating that patients with a high stroma content do not benefit
from VEGF inhibition (supplementary Tables S4A and B, avail-
able at Annals of Oncology online).
Multivariate analyses of prognostic factors for CSS
Multivariate analyses of the individual datasets are summarised
in supplementary Tables S2A–F, S3A-D and S5A-C, available at
Annals of Oncology online.
The pooled dataset comprising QUASAR 2, Gloucester and
Aker populations are summarised in Tables 2 and 3. In multivari-
ate modelling, the dominant contributory factors for stage II dis-
ease were the combination of ploidy and stroma [P< 0.001, HR
1.77 (95% CI: 1.13–2.77)] for the intermediate- versus low-risk
group and HR 2.95 (95% CI: 1.73–5.03) for the high- versus low-
risk group), pathological stage T4 versus T3 [HR 1.99 (95% CI:
1.35–2.93), P< 0.001], utilisation of adjuvant chemotherapy [HR
0.44 (95% CI: 0.29–0.69), P< 0.001] and age [HR 1.02 (95% CI:
1.00–1.04), P¼ 0.011]. It was considered reasonable to pool these
datasets as we prepared a multivariate model in which adjuvant
chemotherapy (yes/no) was included as a covariate in this analysis.
This showed that adjuvant chemotherapy does not change the HRs
for ploidy/stroma. Without adjuvant treatment as covariate: HR
1.77 (95% CI: 1.15–2.70) for the intermediate-risk group and HR
2.83 (95%CI: 1.68–4.76) for the high-risk group.
In stage III, significant factors included histological grade [HR
1.36 (95% CI: 0.67–2.76) for moderately versus well differenti-
ated tumours and HR 1.96 (95% CI: 0.95–4.07) for poorly versus
well differentiated tumours, P¼ 0.010], pathological T-stage
[HR 0.89 (95% CI: 0.50–1.59) for pT3 versus pT2 tumours and
HR 1.84 (95% CI: 1.03–3.29) for pT4 versus pT2, P< 0.001] and
adjuvant treatment [HR¼ 0.37 (95% CI: 0.29–0.47), P< 0.001,
Table 3].
Relapse-free survival was available for the QUASAR 2 and Aker
populations and these data are shown in supplementary Tables
S3A–D, available atAnnals of Oncology online. Interestingly, there
is a stronger multivariate association between ploidy/stroma for
stage II patients using this end point.
Discussion
Like most epithelial tumours, CRCs are composed of two inter-
dependent cellular compartments: malignant epithelium and
tumour stroma. Tumour stroma (consisting of extracellular
matrix admixed with fibroblasts, myofibroblasts, endothelial cells
and inflammatory and immune infiltrative cells) is considered to
make a critical contribution to tumour biology in terms of sur-
vival, growth, invasion andmetastatic potential.
Recently, tumour-stromal measurement utilising visual esti-
mation has been applied to tissue sections from 710 patients
enrolled in the VICTOR trial, suggesting that tumours compris-
ing more than 50% stroma have significantly poorer prognosis
[12]. The explanation for the effect described here is currently
unknown, but there are data to suggest that there may be
enhanced pro-invasive signalling by intra-stromal myofibroblasts
or growth factor/cytokine production by cancer-associated fibro-
blasts inducing enhanced angiogenesis, increased tumour growth
and invasion, possibly through induction of a mesenchymal stem
cell phenotype. Guinney et al. [22] used gene expression profiles
to define several subtypes of colorectal cancer, one of which,
CMS4, showed significant upregulation of genes implicated in
epithelial-to-mesenchymal transition and of signatures compati-
ble with stromal infiltration. More recently Isella et al. [23] have
shown that the distinctive transcriptional and clinical features of
this subtype can be ascribed to its particularly abundant stromal
component, consistent with findings in the current study. Angell
and Galon [16] have explored the prognostic impact of immune
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infiltrates. Using digital quantification of CD3 and CD8 lympho-
cytes following immunohistochemical staining, they suggest that
a low immune infiltrate score is associated with a higher relapse
rate. Recently, Mlecnik et al. demonstrated the presence of func-
tional mutation-specific cytotoxic T cells and the superiority of
immunoscore over MSI in predicting survival, as is the case with
the ploidy/stroma assay [24].
The association between ploidy and poor prognosis is well
documented (reviewed in [25]). Current opinion is that damage
to the cellular apparatus of mitosis within epithelial tumours at
an early stage can produce cells with chromosomal instability and
that these genetically unstable cells drive tumorigenesis by
producing progeny with diverse (uncharacterised) genetic altera-
tions conferring survival advantages.
Individually, mutations in TP53, PIK3CA and KRAS are very
weak prognostic markers. BRAF, which is prognostic in advanced
CRC, is much less so for the primary tumour [8]. Most of these
studies have suffered from small sample size, poorly curated tis-
sue banks, inadequate validation on independent datasets and a
lack of assay quality control. Morphometric analyses of ploidy
and stroma (Figure 1A) has provided a technically simple prog-
nostic stratifier for stage II CRC which is likely to be clinically
useful. By defining a substantial proportion (34%) of patients
with good prognosis (90% 5-year CSS), it will inform discussion
A Pooled dataset stage II
P < 0.001
HR D and LS=1.0
HR D and HS/ND and LS=1.8 (1.2–2.7)
HR ND and HS=2.9 (1.7–4.8)
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0
B Pooled dataset stage III
P = 0.050
HR D and LS=1.0
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Figure 1. Kaplan–Meier plots illustrating cancer-speciﬁc survival (CSS) for patients with tumours that were diploid and low stroma (D and
LS), diploid and high stroma or non-diploid and low stroma (D and HS/ND and LS), and non-diploid and high stroma (ND and HS) among
(A) patients with stage II tumours and (B) patients with stage III tumours.
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with the patient as to the absolute benefits of adjuvant chemo-
therapy. The HR, separating relatively good from relatively poor
prognosis [HR 2.95 (95% CI: 1.73–5.03, P< 0.001] for the
ploidy-stromal classifier is superior to the HR generated for stage
II colon cancer patients by the RNA signature [11] Oncotype Dx
ColonTM (HR¼ 1.47, P¼ 0.046), although no direct comparison
of the two tests has been made. For patients with high stroma that
undergo adjuvant therapy, reports indicate that this group of
patients have shorter survival and thus that further substratifica-
tion is required [15]. Although digital pathology is widely avail-
able, the ploidy element of the assay needs to be established in
accredited central laboratories, which offer the most practical,
initial means of delivering the assay.
This combined biomarker was not prognostic for stage III
CRC, where the clinical default is to offer patients combination
adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin.
As shown in Figure 2C, it might be possible to challenge this para-
digm and consider single agent chemotherapy for the low-risk
group, particularly in elderly patients.
Although there is significant international variation in clinical
practice, in the UK, around 50% of stage II colon cancer patients
receive adjuvant chemotherapy, a proportion of which is admin-
istered in combination, overtreating the general population of
patients so that a small minority might benefit. The use of this
new prognostic biomarker will identify approximately 34% of
stage II patients with a prognosis similar to stage I patients who
A B
C
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Pooled dataset stage III
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Figure 2. Kaplan–Meier plots illustrating cancer-speciﬁc survival (CSS) for patients stratiﬁed by pathological stage and histological grade in the
pooled dataset. (A) Stage II disease. (B) Stage III disease. (C) Stage III disease—aggregated version grouped as pT1 or pT2 (Low pT/diff.), pT3 or
well- or moderately differentiated pT4 tumours (Intermediate pT/diff.), and pT4 and poorly differentiated tumours (pT4 and poorly diff.).
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might therefore avoid adjuvant treatment, 55% of intermediate
prognosis who might benefit from adjuvant fluoropyrimidine
monotherapy and 11% with a bad prognosis of whom the patient
and clinician might consider that combination therapy with oxa-
liplatin would be merited, in patients under 70 years of age.
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